| The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2016 · chromium group · Women with polycystic ovary syndrome (PCOS) | 200 mcg | 8 weeks | 30 |
| Effects of chromium picolinate on beginning weight training students 1992 · M-CrPic · Male college-age students beginning a weight-lifting program | 200 mcg | 12 weeks | 18 |
| Effects of chromium picolinate on beginning weight training students 1992 · F-CrPic · Female college-age students beginning a weight-lifting program | 200 mcg | 12 weeks | 12 |
| [Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet] 1997 · chromium yeast · Obese, non-diabetic patients aged 45 ± 6 years undergoing a very-low-calorie diet and maintenance period | 200 mcg | 26 weeks | — |
| [Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet] 1997 · chromium-picolinate · Obese, non-diabetic patients aged 45 ± 6 years undergoing a very-low-calorie diet and maintenance period | 200 mcg | 26 weeks | — |
| A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving 2005 · chromium picolinate (CrPic) · Adults with atypical depression; most were overweight or obese | 600 mcg | 8 weeks | 70 |
| Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus 2010 · Chromium group · Adults aged 30–70 with type 2 diabetes mellitus, BMI 25–40, and fasting plasma glucose at screening of at least 125 mg/dL | 1 mg | 24 weeks | 70 |
| Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation 2007 · chromium · Adults aged 25–70 with type 2 diabetes mellitus | 1 mg | 26 weeks | 38 |
| Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus 2005 · Group A · Patients with type 2 diabetes mellitus | 1 mg | 90 days | 30 |
| Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus 2005 · Group B · Patients with type 2 diabetes mellitus | 1 mg | 90 days | 30 |
| Effects of niacin-bound chromium supplementation on body composition in overweight African-American women 1999 · niacin-bound chromium (verum period) · overweight African-American women participating in a modest diet-and-exercise regimen | 600 mcg | 60 days | 18 |
| A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study 2013 · high dose · Adults aged 18–60 with binge eating disorder and BMI 25–45; mostly women | 1 mg | 26 weeks | 7 |
| A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study 2013 · moderate dose · Adults aged 18–60 with binge eating disorder and BMI 25–45; mostly women | 600 mcg | 26 weeks | 7 |
| Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes 1997 · 1.92 micromol (100 microg) Cr as chromium picolinate two times per day · Men and women with type 2 diabetes receiving treatment | 200 mcg | 120 days | — |
| Chromate-allergic patients challenged orally with potassium dichromate 1994 · potassium dichromate challenge · 30 patients with positive patch tests to potassium dichromate | 2.5 mg | 1 day | 30 |
| Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator? 2024 · Group A (intervention group; trivalent chromium) · Adults with rheumatoid arthritis; predominantly female; mean age 42.9 years in this group | 0.0035 mg/kg | 12 weeks | 20 |
| Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance 2018 · Cr-enriched yeast · Patients with metabolic syndrome and impaired glucose tolerance; age and sex not specified | 300 mcg | — | — |
| Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes 1997 · 9.6 micromol (500 microg) Cr two times per day · Men and women with type 2 diabetes receiving treatment | 1 mg | 120 days | — |
| [Clinical assessment of dietary correction of metabolic syndrome by using specialized food product enriched with chrome] 2013 · Main group · Adults aged 30–65 years with metabolic syndrome | 66 mcg | 26 weeks | 20 |
| Effects of an amylopectin and chromium complex on the anabolic response to a suboptimal dose of whey protein 2017 · WPACr (whey protein isolate + Velositol test product) · Healthy men and women aged 22–34 years | 2 g | 1 day | 10 |
| Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss 2004 · Group B · Adults aged 21–50 with moderate obesity (BMI >26 kg/m²) | 4 mg | 8 weeks | — |
| Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control 2005 · group B · Obese adults with BMI 30–50.8 kg/m² | 4 mg | 8 weeks | — |
| [Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China] 2012 · study group · Adults with newly diagnosed type 2 diabetes mellitus; age and sex not reported | 480 mg | 24 weeks | 42 |
| Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial 2025 · herbal supplement · Adults aged 18–75, male and female, otherwise healthy and self-reporting stress (PSS score ≥13) | 40 mcg | 15 days | 35 |
| Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2015 · chromium picolinate supplements · Women with polycystic ovary syndrome (PCOS) | 200 mcg | 8 weeks | 32 |
| A comparative study to assess the use of chromium in type 2 diabetes mellitus 2023 · chromium supplement group · Patients aged 40–60 years with uncontrolled type 2 diabetes mellitus | 400 mcg | 90 days | 30 |
| The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects 1990 · chromium picolinate · Adult volunteer subjects; sex and age range not reported; no condition stated | 200 mcg | 6 weeks | 28 |
| In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: a randomized, double-blind, placebo controlled trial 2010 · chromium-nicotinate group · HIV-positive adults with insulin resistance and elevated glucose, lipids, or evidence of body-fat redistribution | 400 mcg | 16 weeks | 23 |
| The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial 2020 · CrPic supplement · patients with type 2 diabetes mellitus; age and sex not stated | 500 mcg | 120 days | 23 |
| Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial 2021 · chromium picolinate group · Adults aged 20–65 with nonalcoholic fatty liver disease | 400 mcg | 12 weeks | 23 |
| A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial 2021 · chromium picolinate · Patients with nonalcoholic fatty liver disease (NAFLD); age and sex not reported | 400 mcg | 90 days | 23 |
| Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients 2011 · Cr brewer's yeast · Adults aged 37–63 with type 2 diabetes | 500 mcg | 8 weeks | 20 |
| The Influences of Chromium Supplementation on Glycemic Control, Markers of Cardio-Metabolic Risk, and Oxidative Stress in Infertile Polycystic ovary Syndrome Women Candidate for In vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · chromium group · Women aged 18–40 with infertility and polycystic ovary syndrome who were candidates for in vitro fertilization | 200 mcg | 8 weeks | 20 |
| Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus 2006 · Cr-enriched yeast group · Adults with type 2 diabetes mellitus; mean age 61.3 years; 9 men and 27 women across the study | 400 mcg | 12 weeks | 19 |
| Effects of acute chromium supplementation on postprandial metabolism in healthy young men 2004 · 400 microg chromium group · Apparently healthy, non-smoking young men with normal body mass index | 400 mcg | 1 day | 13 |
| Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study 2000 · chromium polynicotinate · Hypercholesterolemic subjects with total cholesterol 210–300 mg/dL; age and sex not reported | 400 mcg | 8 weeks | 10 |
| The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes 2000 · CrCl3 · People with type 2 diabetes; age and sex not specified | 200 mcg | 8 weeks | — |
| The effects of chromium and copper supplementation on mitogen-stimulated T cell proliferation in hypercholesterolaemic postmenopausal women 2002 · 200 microg Cr · Hypercholesterolaemic postmenopausal women | 200 mcg | 12 weeks | — |
| The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial 2006 · chromium-containing milk powder group · Adults aged 30 to 75 years with type 2 diabetes mellitus, taking gliclazide | 400 mcg | 16 weeks | — |
| Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study 2012 · chromium dinicocysteinate · Adults aged 25–65 with type 2 diabetes | 400 mcg | 90 days | — |
| Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study 2012 · chromium picolinate · Adults aged 25–65 with type 2 diabetes | 400 mcg | 90 days | — |
| Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial 2020 · group III: chromium picolinate (CrPic) · People with type 2 diabetes mellitus; age and sex not stated | 500 mcg | 120 days | — |
| Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial 2007 · chromium picolinate and biotin combination (CPB) · Adults with type 2 diabetes mellitus and HbA1c ≥7%; supplemental analyses included participants with hypercholesterolemia and participants using stable doses of statins | 600 mcg | 90 days | 226 |
| Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial 2016 · Chromium picolinate group · Women with polycystic ovary syndrome; age range not reported | 1 mg | 26 weeks | 44 |
| Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study 2015 · supplemented · Patients with poorly controlled type 2 diabetes mellitus (HbA1c >7%); age and sex not reported | 600 mcg | 120 days | 32 |
| Synchronizing positive effect of vitamin C and chromium on hyper lipidemia, hyperglycemia, liver enzymes and BMI of diabetes mellitus type 2 patients 2024 · treatment group · Adults with type 2 diabetes mellitus; age range and sex breakdown for this arm not specified | 200 mcg | — | 30 |
| Effects of acute chromium supplementation on postprandial metabolism in healthy young men 2004 · 800 microg chromium group · Apparently healthy, non-smoking young men with normal body mass index | 800 mcg | 1 day | 13 |
| Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study 2000 · combination of chromium polynicotinate and grape seed extract · Hypercholesterolemic subjects with total cholesterol 210–300 mg/dL; age and sex not reported | 400 mcg | 8 weeks | 10 |
| A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation 2017 · MOD · Overweight individuals with binge-eating disorder; age and sex not specified | 600 mcg | 26 weeks | 9 |
| A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation 2017 · HIGH · Overweight individuals with binge-eating disorder; age and sex not specified | 1 mg | 26 weeks | 8 |
| The effects of chromium and copper supplementation on mitogen-stimulated T cell proliferation in hypercholesterolaemic postmenopausal women 2002 · 200 microg Cr and 3.0 mg Cu · Hypercholesterolaemic postmenopausal women | 200 mcg | 12 weeks | — |
| Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial 1991 · chromium group · Men taking beta-blockers, mainly for hypertension | 600 mcg | 8 weeks | — |
| Effect of chromium supplementation on glucose tolerance and lipid profile 2000 · Chromium supplement · Normal, free-living adults; age and sex not specified | 200 mg | 8 weeks | 44 |
| The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes 2000 · Brewer's yeast · People with type 2 diabetes; age and sex not specified | 23.3 mcg | 8 weeks | — |
| Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes 2011 · study group · People with newly onset type-2 diabetes | 42 mcg | 90 days | — |
| Effects of Chromium and Carnitine Co-supplementation on Body Weight and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2020 · supplement group · Overweight women with polycystic ovary syndrome (PCOS) | 200 mcg | 12 weeks | 27 |
| A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial 2015 · Dietary supplement (Glycabiane) · Adults aged 25–65 years, overweight or obese, with pre-diabetes/impaired fasting glucose | 20 mcg | 120 days | 26 |
| The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial 2020 · both vitamin D3 and CrPic · patients with type 2 diabetes mellitus; age and sex not stated | 500 mcg | 120 days | 23 |
| Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health, Fitness, and Weight Loss in Men and Women with Risk Factors to Metabolic Syndrome Initiating an Exercise and Diet Intervention: A Randomized Double-Blind, Placebo-Controlled Trial 2025 · Cr-800 · Sedentary men and women aged 30–65 with overweight/obesity and at least two risk factors for metabolic syndrome | 800 mcg | 12 weeks | 23 |
| Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health, Fitness, and Weight Loss in Men and Women with Risk Factors to Metabolic Syndrome Initiating an Exercise and Diet Intervention: A Randomized Double-Blind, Placebo-Controlled Trial 2025 · Cr-400 · Sedentary men and women aged 30–65 with overweight/obesity and at least two risk factors for metabolic syndrome | 400 mcg | 12 weeks | 18 |
| Impact of a mineral enriched, fiber complex on glycaemic response and satiation in healthy adults: a double-blind, crossover intervention study 2025 · SBD (SlimBiome® + dextrose) · Healthy men and women aged 18–65 years with normal fasting glucose and BMI 18.5–24.9 kg/m² | 15 mcg | 1 day | 16 |
| The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial 2006 · Chromium picolinate and biotin · People with type 2 diabetes and suboptimal glycemic control despite oral antihyperglycemic agents | 600 mcg | 4 weeks | — |
| Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial 2020 · group IV: vitamin D3 and CrPic · People with type 2 diabetes mellitus; age and sex not stated | 500 mcg | 120 days | — |
| Efficacy and Tolerability of a Food Supplement Based on Zea mays L., Gymnema sylvestre (Retz.) R.br.ex Sm, Zinc and Chromium for the Maintenance of Normal Carbohydrate Metabolism: A Monocentric, Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2024 · Group 1 (two FS tablets) · Adults aged 18–75 years, either sex, with mildly impaired fasting blood glucose (98–125 mg/dL) | 40 mg | 90 days | 27 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical A · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 10 mcg | 6 weeks | 24 |